How can the industry address the technical and financial barriers to developing advanced controlled release systems, given their 40-50% higher production costs compared to conventional formulations?
The industry must adopt a science-driven, data-informed development strategy. A foundational understanding of the active pharmaceutical ingredient’s (API) physicochemical properties, the matrix characteristics, and the drug’s pharmacokinetic (PK) and pharmacodynamic (PD) profiles is essential. Leveraging these insights early in development facilitates rational formulation design, enhances technology selection, and supports a quality-by-design (QbD) framework. This approach not only improves development efficiency and reduces costly trial-and-error iterations but also enables the creation of patient-centric dosage forms that align with therapeutic goals and regulatory expectations.
What emerging technologies (e.g., AI-optimized release profiles, robotic dosing systems, bioresorbable implants) show the most promise for overcoming current drug delivery limitations?
AI enables the design of more precise release profiles by integrating and helping to interpret diverse datasets, including physicochemical properties, absorption kinetics, and patient-specific factors. These tools can accelerate formulation development and improve clinical success rates.
Continued advancements in biomodelling allow for more accurate simulations of drug absorption and disposition. These models, grounded in human physiology, are increasingly replacing reliance on traditional animal studies, which often lack translational fidelity.
Micro-engineered systems that mimic human tissues and physiological functions provide a scalable, ethically sound alternative to in vivo studies. These platforms support rapid screening of controlled release technologies under dynamic, human-relevant conditions. Innovations such as “smart pills” can incorporate sensors, actuators, or microelectronics to monitor and modulate drug release in real time. These technologies offer potential for personalized therapy and adaptive dosing in complex conditions.
Progress in bioresorbable polymers and tunable hydrogels enables more targeted and consistent release, particularly in overcoming interpatient variability related to pH, motility, or enzymatic activity. These materials also support implantable or depot formulations with improved biocompatibility.
Collectively, these tools and platforms are not only enhancing performance and reliability but also aligning with regulatory trends toward modeling, simulation, and individualized therapeutics.
How should regulatory strategies evolve to accelerate approval of novel controlled release platforms while ensuring patient safety, particularly for combination products?
Regulatory strategies must evolve to both safeguard patient outcomes and facilitate the timely approval of novel controlled release platforms, particularly those involving combination products. While the development landscape is complex and multifactorial, several targeted areas can accelerate progress:
Adoption of more physiologically relevant non-clinical models - especially those that replicate human gastrointestinal (GI) tract, metabolic, or tissue conditions - can improve the predictiveness of early safety and performance assessments. This shift would reduce the translational gap and foster confidence in moving to clinical trials.
The use of advanced, small-scale manufacturing platforms that better mimic commercial-scale processes enables early generation of material that is representative of final dosage forms. This alignment allows stability, PK, and performance data collected during early development to remain relevant and supportive through late-stage development and regulatory review.
Regulatory frameworks may benefit from adopting adaptive approval models, particularly for controlled release systems targeting small or stratified patient populations. Drawing on precedents from oncology and rare disease programs, early conditional approvals based on surrogate endpoints or strong mechanistic rationale could support innovation while preserving safety through post-market surveillance.
What criteria determine whether existing immediate-release drugs should be reformulated as controlled-release versions?
The decision to reformulate an immediate-release (IR) drug into a controlled-release (CR) version is multifactorial, involving scientific, clinical, commercial, and increasingly, payer-driven considerations.
A strong rationale often centers on improving the safety profile by reducing peak plasma concentrations (Cmax), which may otherwise drive dose-related adverse effects. Controlled release profiles can mitigate these peaks, reducing variability and improving tolerability, especially in drugs with narrow therapeutic windows. CR formulations may reduce dosing frequency, which is especially beneficial for chronic conditions and drives improved adherence, which in turn translates into better therapeutic outcomes and long-term healthcare savings - an increasingly persuasive argument for payers and providers.
When the therapeutic effect is linked to sustained exposure rather than high peak levels, CR formulations can enhance efficacy and minimize fluctuations that impact clinical response or side effects.
Bioequivalence (BE), efficacy, and safety must still be demonstrated for the reformulated product, often requiring additional clinical work. Technologies with a strong history of regulatory acceptance and scalable manufacturing processes are generally favored.
From an ROI perspective, transitioning a drug to a CR formulation can extend market exclusivity, differentiate the product in a crowded therapeutic space, and support pricing premiums over generic and IR forms, particularly if the new form addresses unmet clinical needs or simplifies complex regimens.
How does this decision impact lifecycle management and ROI?
Controlled release will require clinical data for BE, safety, and efficacy, but can also increase patient compliance and minimize side effects by blunting elevated exposure associated with Cmax. The quality profile of controlled release formulations should also be understood to ensure a robust release mechanism to both process parameters and for varying patient physiologies.
Therapeutic areas such as cardiovascular and metabolic diseases stand to benefit significantly. The body’s hormonal and peptide signaling systems - central to these areas - are governed by finely tuned kinetic patterns. As our understanding of their interconnectivity deepens, the demand for more precise and sustained PK control will increase, making CR strategies increasingly valuable.
Although a scientific rationale is critical, payer influence is often decisive. Health technology assessments and formulary decisions may hinge on whether the CR formulation demonstrates clear advantages in compliance, safety, or quality-of-life metrics, ideally backed by real-world data.
Which therapeutic areas (e.g., oncology, diabetes, CNS disorders) present the strongest opportunities for next-generation controlled release applications through 2030?
The future of oncology is increasingly defined by personalized medicine and combination regimens that target multiple cellular pathways to prevent resistance and relapse. CR systems can support these paradigms by enabling staggered or synchronized release of multiple agents to maximize synergy and minimize toxicity, and maintaining low, sustained exposure to reduce systemic side effects while maintaining efficacy in sensitive tissues.
Diabetes and other metabolic diseases are characterized by interlinked hormonal signaling cascades, requiring precise PK control of one or more therapeutic agents. Controlled release systems can deliver combinations of peptides or small molecules with distinct absorption profiles to mirror physiological rhythms. Specifically, improving adherence and reducing patient burden and stabilizing plasma level, and dampening post-prandial excursions.
Conditions affecting the CNS, such as schizophrenia, depression, and Parkinson’s disease, present unique challenges in long-term medication adherence and maintaining steady therapeutic levels. CR technologies are well-suited to extend dosing intervals, avoiding PK fluctuations that can otherwise cause side effects, breakthrough symptoms, or loss of therapeutic effect.
How can continuous manufacturing technologies improve the commercial viability of controlled release products while meeting strict quality control requirements?
Continuous manufacturing (CM) presents a compelling opportunity to enhance the commercial viability and regulatory robustness of CR drug products. These platforms support both agile production and strict quality control through several key advantages, as one of the primary advantages of CM is reducing the time and cost associated with transferring processes from pilot to commercial scale. Also, enabling early development on production-representative equipment, allowing clinical and stability data to remain relevant throughout the product lifecycle.
Incorporation of process analytical technology (PAT) tools enables continuous, in-line monitoring of critical quality attributes (CQAs), and immediate detection and correction of process deviations, minimizing batch failures and ensuring consistent product performance.
These capabilities provide a higher level of quality assurance, which is especially valuable in complex CR formulations.
The flexibility of CM also supports emerging trends in precision medicine and small-batch production, making it well-suited for tailoring dosage forms to specific patient subgroups (e.g., based on genetics, metabolism, or disease stage) and on-demand production, reducing inventory waste and improving responsiveness to market or clinical needs.
As CR therapies become more personalized, particularly in oncology, CNS, and rare diseases, CM offers a scalable yet nimble production solution.
What balance should innovators strike between developing cutting-edge controlled release systems and ensuring accessibility in cost-sensitive markets?
Cost eff ectiveness is the result of intentional technology development with an emphasis on fundamental understanding of materials properties, process considerations and platform applications. To enable cutting-edge technologies, being diligent about the holistic Explore the Latest Featured Products Online program and product lifecycle can ensure efficient development and manufacturing, which in turn reduces cost.
Achieving cost efficiency starts with a fundamental understanding of material properties, process dynamics, and delivery platform capabilities. When technologies are developed with scalability and manufacturability in mind, there is a reduced risk of late-stage redesign or cost-prohibitive production challenges. This “riright-first-timeapproach, rooted in scientific rigor and platform thinking, supports both innovation and affordability.
As the industry shifts from mass-market “blockbuster” therapies to targeted treatments for niche or stratified populations, there is a greater opportunity for payers to support premium therapies at manageable cost. Smaller patient populations allow for pricing structures that reflect therapeutic value without overwhelming healthcare budgets.
Moreover, technologies that demonstrably improve compliance, safety, and long-term outcomes - hallmarks of well-executed CR strategies - can generate favorable pharmacoeconomic data that support reimbursement in both developed and emerging markets.
Ultimately, the goal is not to compromise innovation, but to pursue it intelligently, with an emphasis on translational feasibility, manufacturability, and equitable access. This requires cross-functional collaboration from the earliest stages of development and a commitment to delivering value across the entire healthcare ecosystem.
Author Details
Scott Bone, Head of Formulation and Process Science, Bend Bioscience
Publication Details
This article appeared in American Pharmaceutical Review:Vol. 28, No. 4
May/June 2025Pages: 56-58
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!